He had heard of BPC-157 but did not know enough about it to give medical advice
The FDA issued a warning letter regarding BPC-157 compounding in 2023, noting that bulk drug substances used in 503A compounding must meet specific quality standards
44 Orforglipron In a phase 2, randomized, double-blind trial, daily oral orforglipron (12, 24, 36, or 45 mg) for 36 weeks led to weight reductions of 9.414.7% in adults with pre-obesity or obesity (without diabetes), compared to 2.3% with placebo, and showed no signs of plateau (Table 2)
Emphasizing a patch test and close follow-up can help mitigate side effects
Many Jacksonville residents have experienced remarkable success stories after using this combination, losing up to a pound a day and achieving their weight-loss goals in no time
This article draws on available Phase 2 trial data and related incretin therapy experience to provide clear, evidence-informed guidance